EGFR and hepatocellular carcinoma: EGFR TKIs improve the survival rate of HCC patients, but the rapid genetic mutations and epigenetic mutation of EGFR tyrosine kinase domain and other drug resistance mechanisms that do not depend on EGFR make many patients develop drug resistance in long-term treatment.